- Home
- BLRX vs CRIS Comparison
BLRX vs CRIS Comparison
Compare BLRX & CRIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- CRIS
- Stock Information
- Founded
- BLRX 2003
- CRIS 2000
- Country
- BLRX Israel
- CRIS United States
- Employees
- BLRX N/A
- CRIS N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BLRX Health Care
- CRIS Health Care
- Exchange
- BLRX Nasdaq
- CRIS Nasdaq
- Market Cap
- BLRX 12.1M
- CRIS 13.5M
- IPO Year
- BLRX 2011
- CRIS 2000
- Fundamental
- Price
- BLRX $5.25
- CRIS $2.46
- Analyst Decision
- BLRX Strong Buy
- CRIS Strong Buy
- Analyst Count
- BLRX 2
- CRIS 2
- Target Price
- BLRX $19.00
- CRIS $16.50
- AVG Volume (30 Days)
- BLRX 1.9M
- CRIS 89.6K
- Earning Date
- BLRX 05-27-2025
- CRIS 05-06-2025
- Dividend Yield
- BLRX N/A
- CRIS N/A
- EPS Growth
- BLRX N/A
- CRIS N/A
- EPS
- BLRX N/A
- CRIS N/A
- Revenue
- BLRX $22,340,000.00
- CRIS $11,202,000.00
- Revenue This Year
- BLRX N/A
- CRIS $2.15
- Revenue Next Year
- BLRX N/A
- CRIS $5.08
- P/E Ratio
- BLRX N/A
- CRIS N/A
- Revenue Growth
- BLRX 91.68
- CRIS 14.17
- 52 Week Low
- BLRX $2.30
- CRIS $1.02
- 52 Week High
- BLRX $35.60
- CRIS $10.99
- Technical
- Relative Strength Index (RSI)
- BLRX 84.90
- CRIS 65.60
- Support Level
- BLRX $3.32
- CRIS $1.92
- Resistance Level
- BLRX $3.97
- CRIS $2.19
- Average True Range (ATR)
- BLRX 0.46
- CRIS 0.21
- MACD
- BLRX 0.14
- CRIS 0.03
- Stochastic Oscillator
- BLRX 47.06
- CRIS 100.00
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.